title: A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function.
abstract: This study assays therapy with basiliximab and different patterns of cyclosporin A (CsA) initiation in renal transplant (RT) recipients from expanded criteria donors (ECD) and at high risk of delayed graft function (DGF). A multicentre six-month open-label randomized trial with three parallel groups treated with basiliximab plus steroids, mycophenolate mofetil and different patterns of CsA initiation: early within 24 h post-RT at 3 mg/kg/d (Group 1; n = 38), and at 5 mg/kg/d (Group 2; n = 40), or delayed after 7-10 d at 5 mg/kg/d (Group 3; n = 36). There were no differences among groups in six months GFR (43.1 +/- 12, 48.0 +/- 14 and 47.2 +/- 17 mL/min, respectively), DGF (Group 1: 31%, Group 2: 37%, Group 3: 42%), nor biopsy-proven acute rejection, although clinically treated and biopsy-proven acute rejection was significantly higher in Group 3 (25%) vs. Group 1 (5.3%, p < 0.05). At six months no differences were observed in death-censored graft survival or patient survival. Induction therapy with basiliximab and three CsA-ME initiation patterns in RT recipients from ECD and at high risk of DGF presented good renal function and graft survival at six months. Late onset group did not achieve improvement in DGF rate and showed a higher incidence of clinically treated and biopsy-proven acute rejection.
authors.affiliation: Nephrology Service, Hospital 12 de Octubre, Madrid, Spain. aandres.hdoc@salud.madrid.org
authors.forename: Amado
authors.initials: A
authors.lastname: Andrés
authors.forename: Roberto
authors.initials: R
authors.lastname: Marcén
authors.forename: Francisco
authors.initials: F
authors.lastname: Valdés
authors.forename: Jaime Sánchez
authors.initials: JS
authors.lastname: Plumed
authors.forename: Ricard
authors.initials: R
authors.lastname: Solà
authors.forename: Pedro
authors.initials: P
authors.lastname: Errasti
authors.forename: Ricardo
authors.initials: R
authors.lastname: Lauzurica
authors.forename: Luis
authors.initials: L
authors.lastname: Pallardó
authors.forename: Jesús
authors.initials: J
authors.lastname: Bustamante
authors.forename: Juan José
authors.initials: JJ
authors.lastname: Amenábar
authors.forename: Juan José
authors.initials: JJ
authors.lastname: Plaza
authors.forename: Ernesto
authors.initials: E
authors.lastname: Gómez
authors.forename: Josep Maria
authors.initials: JM
authors.lastname: Grinyó
authors.forename: Manuel
authors.initials: M
authors.lastname: Rengel
authors.forename: Josep Maria
authors.initials: JM
authors.lastname: Puig
authors.forename: Aurelio
authors.initials: A
authors.lastname: Sanz
authors.forename: Concepción
authors.initials: C
authors.lastname: Asensio
authors.forename: Inés
authors.initials: I
authors.lastname: Andrés
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D016572:Cyclosporine / Q000627:therapeutic use*; D051799:Delayed Graft Function; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy / Q000276:immunology; D006085:Graft Survival / Q000187:drug effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007677:Kidney Function Tests; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011446:Prospective Studies; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D016572:Cyclosporine; D000077552:Basiliximab; D009173:Mycophenolic Acid